Business news for the stock market
Biofrontera AG: Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
Leverkusen (pta046/26.02.2021/15:20) - Leverkusen, Germany, February 26, 2021- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) ( Biofrontera or the Company ), an international biopharmaceutical company, announces the closing of the capital increase resolved by the annual general meeting on May 28, 2020.
The capital increase was carried out by way of a subscription rights offering to existing shareholders of Biofrontera AG under German law. Unsubscribed shares were placed in the course of a public offering of American Depositary Shares ( ADS and ADS Offering ) in the United States. The Company raised total gross proceeds of approximately EUR 24.7 million.
DGAP-Ad-hoc: PAION AG / Key word(s): Miscellaneous
PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION
29-Jan-2021 / 11:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO
(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION
- Positive CHMP opinion based on the data from a comprehensive clinical program in procedural sedation in adult patients undergoing bronchoscopy or colonoscopy
- Final decision on MAA expected in the first half of 2021
PAION AG
ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
DGAP-News: PAION AG / Key word(s): Product Launch
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
28.01.2021 / 07:06
The issuer is solely responsible for the content of this announcement.
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
- Approximately 40 million procedures take place annually in the U.S. that require the use of procedural sedation
DGAP-News: PAION AG / Key word(s): Product Launch
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
28.01.2021 / 07:06
The issuer is solely responsible for the content of this announcement.
PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
- Approximately 40 million procedures take place annually in the U.S. that require the use of procedural sedation
- BYFAVO(TM) is the second Acacia Pharma product approved and launched in the U.S. in the last year and extends its portfolio of new products targeting unmet needs in anesthesia
Nachricht vom 28.01.2021 | 13:26
SHOP APOTHEKE EUROPE: Pooling agreement of several shareholders with voting agreement for more than 26% of the voting rights.
SHOP APOTHEKE EUROPE N.V. / Key word(s): Miscellaneous
SHOP APOTHEKE EUROPE: Pooling agreement of several shareholders with voting agreement for more than 26% of the voting rights.
28-Jan-2021 / 13:26 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
SHOP APOTHEKE EUROPE: Pooling agreement of several shareholders with voting agreement for more than 26% of the voting rights